Maia Wealth LLC Purchases 896 Shares of Novartis AG (NYSE:NVS)

Maia Wealth LLC lifted its position in shares of Novartis AG (NYSE:NVS) by 37.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,264 shares of the company’s stock after purchasing an additional 896 shares during the period. Maia Wealth LLC’s holdings in Novartis were worth $337,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Legacy Investment Solutions LLC bought a new position in Novartis during the 3rd quarter worth $28,000. Human Investing LLC acquired a new position in shares of Novartis in the fourth quarter valued at about $25,000. Union Bancaire Privee UBP SA bought a new position in Novartis during the fourth quarter worth about $27,000. Kestra Investment Management LLC acquired a new stake in Novartis in the 4th quarter worth about $47,000. Finally, Brooklyn Investment Group bought a new stake in Novartis in the 4th quarter valued at about $55,000. 13.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 8th. Barclays reaffirmed an “underweight” rating on shares of Novartis in a report on Monday, February 3rd. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Morgan Stanley assumed coverage on Novartis in a research note on Wednesday, February 12th. They issued an “underweight” rating for the company. Finally, Erste Group Bank reissued a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $123.38.

Novartis Stock Performance

Novartis stock opened at $109.06 on Monday. The stock has a market cap of $222.91 billion, a PE ratio of 18.55, a P/E/G ratio of 1.70 and a beta of 0.58. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92. The business’s 50-day moving average price is $102.60 and its two-hundred day moving average price is $108.00.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. As a group, analysts expect that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.